IGFBP5 Detection Service

Insulin like growth factor binding protein 5 (IGFBP5) is a biomarker with clinical application prospects related to various tumors. As an expert in the field of biomarkers, Creative BioMart Biomarker has an experienced technical team and a mature cancer biomarker detection platform, which can provide customers with fast, accurate and sensitive IGFBP5 test results, helping customers shorten the research cycle and reduce research costs.

IGFBP5 and Cancers

IGFBP is a key regulator of insulin-like growth factors (IGFs) and contains six protein families (IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, IGFBP6), and IGFBP5 is one of them that have the relatively more conserved building blocks. IGFs are a class of growth factors with mitogenic and metabolic activities, which can activate the tyrosine kinase pathway by binding to the receptors on the cell surface. IGFBP5 regulates the function of IGF by binding to the conserved domain of IGF. IGFBP5 is localized in the cytoplasm and nucleus, and its combination with IGF may inhibit physiological activities such as proliferation and differentiation. The IGF system participates in many important functions in the human body, including proliferation, differentiation, tumor migration, and invasion. It can be used in clinical diagnosis and disease pathological development monitoring, such as cancer progression and endocrine responsiveness. IGF is up-regulated during tumorigenesis, and IGFBP5 is thought to regulate tumor proliferation and spread, reflecting the development and metastasis of cancer. Therefore, IGFBP5 is considered to be a biomarker for clinical treatment responses and clinical outcomes of various tumors, such as breast cancer, prostate cancer, lung cancer, bladder cancer, thyroid cancer, cervical cancer, salivary gland cancer, etc. IGFBP5 is differentially expressed in cancer tissues, which may be related to the degree of cell differentiation in different cancers. At the same time, the increase of IGFBP5 level is also related to tumor metastasis and migration, so IGFBP5 can be used in tumor research to indicate whether the tumor has metastasized or migrated. IGFBP5 is related to the prognosis of various cancers, and can be used as a prognostic biomarker for breast cancer, ovarian cancer, glioblastoma, etc., indicating clinical results, response to treatment, and survival rate. IGFBP5 is a promising biomarker in various tumor researches, and also has development potential in the development of cancer drugs.

Schematic view of IGFBP5 and possible regulation in cell proliferation networks Figure 1. Schematic view of IGFBP5 and possible regulation in cell proliferation networks (Güllü, et al. 2012)

Application of IGFBP5 Detection

Plasma and serum IGFBP5 levels as biomarkers to predict different diseases, such as breast cancer, prostate cancer, lung cancer, bladder cancer, thyroid cancer, etc.

Our Advantages

  • Guarantee high accuracy and sensitivity for IGFBP5 detection
  • Ensure high repeatability of IGFBP5 detection
  • Short turn-around time of detection service
  • Competitive price in the market of IGFBP5 detection services
  • Provide multiple IGFBP5 detection methods, including ELISA, colorimetric assay, etc.
  • Accept a wide range of sample types (plasma, serum and cell culture supernates)

Workflow of Biomarker Detection at Creative BioMart Biomarker

Creative BioMart Biomarker strictly controls each specific experimental step in the detection procedure to ensure accurately quantify the level of IGFBP5 in each sample.

HDL Functionality Biomarker Detection Service

At Creative BioMart Biomarker, we offer IGFBP5 detection service that refer to different methods, you can communicate with our experts according to your research needs, and we will determine the final detection technological scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.

References:

  1. Murukesh, N.; et al. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. British Journal of Cancer. 2010, 102(1): 8–18.
  2. Macedo, F.; et al. Gastric cancer and angiogenesis: is VEGF a useful biomarker to assess progression and remission? Journal of Gastric Cancer. 2017, 17(1): 1-10.
  3. Alsohaimi, A. The pathogenic role of vascular endothelial growth factor (VEGF) in skin diseases. Advances in Medicine and Medical Research. 2019, 2(1): 27-37.
  4. Güllü, G.; et al. Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chinese Journal of Cancer. 2012, 31(6): 266-280.

Menu

Contact Us

Subscribe

Enter your email here to subscribe